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Abstract
Life style modifications and optimization of the management of cardio-metabolic comorbidities 
are currently the mainstay of treatment for patients with non-alcoholic fatty liver disease 
(NAFLD). Pharmacotherapy to halt or reverse hepatic histological injury and prevent the 
development of end stage liver disease is specifically offered to patients with non-alcoholic 
steatohepatitis (NASH) and those with advanced fibrosis. In this review, we will discuss state of 
the art of various pharmacological agents for NASH. The efficacy of vitamin E and pioglitazone is 
reasonably well established in a select group of patients with NASH. Current data do not offer 
convincing evidence for efficacy of pentoxifylline, long-chain polyunsaturated fatty acids, 
angiotensin receptor blockers, metformin or ursodeoxycholic acid. We also discuss the state of 
several emerging agents for treating NASH including the farsenoid X receptor (FXR) ligand, 
obeticholic acid.
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Introduction
End stage liver disease (ESLD) due to non-alcoholic steatohepatitis (NASH) is currently the 
second leading indication for liver transplantation in the U.S.(1). NASH is expected to 
replace hepatitis C as the leading indication for liver transplantation within the next decade 
(2) While the progression of non-alcoholic fatty liver (NAFL) to fibrosing NASH has been 
recently been described (3, 4), older literature based on long term follow up studies has 
shown that progression to ESLD or liver related death is rare in these patients (5–7). On the 
other hand, patients with NASH and particularly with underlying fibrosis are at increased 
risk for progression to cirrhosis, liver failure and hepatocellular carcinoma (HCC) (5, 8–10). 
Fibrosis, typically seen as part of NASH, has emerged in several studies as the strongest 
predictor of long term outcomes in patients with NASH (5, 8, 9, 11, 12). While life style 
modifications and optimization of coexisting cardio-metabolic comorbidities have been 
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recommended to all patients with NAFLD, liver directed pharmacotherapy to stop or reverse 
histological injury and to prevent liver related events and death, has been specifically 
targeted toward patients with NASH (13, 14). In this paper, we review the current literature 
pertaining to the efficacy of various pharmacological agents in NASH. Some proof-of-
principle studies that tested therapies in patient with NAFLD but did not include histological 
phenotyping, are also discussed. We also review emerging agents, including those with anti-
fibrotic effects that are in various stages of development.
Drugs with established efficacy in NASH
Vitamin E
In animal models of NASH, vitamin E supplementation reduces hepatic inflammation and 
lipid peroxidation (15). In patients with NASH, vitamin E reduces circulating levels of 
malondialdehyde and transforming growth factor-β1 (16, 17). Further, down-regulation of 
the hedgehog pathway and loss of sonic hedgehog positive hepatocytes, which promote liver 
injury in NASH, have recently been described in patients demonstrating histological 
response to vitamin E (18).
Vitamin E been used alone or with other agents in multiple clinical trials to treat NASH or 
NAFLD, with reported in improvement in liver biochemistries and histology (16, 17, 19–
26), These trials varied in duration (4 to 96 weeks) and dose (100–1200 IU/day) of vitamin 
E used (25, 27). Beneficial effects for vitamin E were demonstrated even in trials of short 
duration; improvement in ALT was reported after 4 weeks and in histology after 6 months of 
vitamin E therapy (17, 21, 25). The best evidence for vitamin E efficacy in NASH comes 
from the PIVENS trial (Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis) 
(23). In this study, 247 adults with biopsy-proven NASH were randomized to receive 
vitamin E (800 IU daily, 84 subjects), pioglitazone (30 mg daily,80 subjects),or placebo (83 
subjects) for 96 weeks. The primary outcome was improvement in histology defined as 
improvement by ≥1 points in ballooning score, no increase in the fibrosis score, and either a 
decrease in the NAFLD activity score (NAS) to ≤3 points or a decrease in NAS of ≤2 points, 
with at least a 1 point decrease in either the lobular inflammation or steatosis score. A p < 
0.025 indicated statistical significance. Vitamin E and pioglitazone significantly improved 
ALT, steatosis, and lobular inflammation but neither drug had a significant effect on hepatic 
fibrosis. Although significantly more patients achieved resolution of NASH only with 
pioglitazone but not vitamin E (47% vs 36% respectively vs 21% for placebo), significant 
improvement in hepatocyte ballooning and achievement of the study primary outcome were 
observed only with vitamin E (Figure 1). This trial did not include patients with diabetes or 
cirrhosis. Similar beneficial effects on NAFLD histology were observed for vitamin E 
children with histologically proven NAFLD included in the TONIC trial (Treatment of 
nonalcoholic fatty liver disease in children) (26). In that study, vitamin E but not metformin 
given for 96 weeks significantly reduced the ballooning grade and NAS. Significantly more 
children had histological resolution of NASH on vitamin E (58%) versus placebo (28%, p 
0.006) but not with metformin (41%, p 0.2).
There is continued debate about long term safety of vitamin E use and its possible 
association with increased mortality and prostate cancer (28–33). Despite these 
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controversies, vitamin E at 800 IU daily is considered a first line therapy for patients with 
histologically confirmed NASH without cirrhosis or type 2 diabetes, according to the current 
multi-society practice guidelines (14).
Thiazolidinediones (TZDs)
Pioglitazone and rosiglitazone improve insulin sensitivity and adiponectin levels but reduce 
the levels of circulating resistin, tumor necrosis factor-α and free fatty acids (34–37). Both 
drugs exhibit a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonistic effect but 
pioglitazone has also a PPAR-α agonistic effect (38).
Several studies have shown favorable effect for both drugs on NAFLD (17, 23, 39–47). As 
detailed above, the PIVENS trial established the efficacy of pioglitazone in improving 
NASH histology (Figure 1) (23). A recent meta-analysis of data from this study in addition 
to two prior trials of pioglitazone in NASH confirmed the improvement in steatosis, lobular 
inflammation, and hepatocyte ballooning (46–48). The pooled data also showed a significant 
improvement in fibrosis with pioglitazone (p 0.04). Prolonged use of pioglitazone may be 
necessary to maintain these effects. In one study, deterioration in ALT, HOMA, adiponectin, 
hepatic steatosis and inflammation were noted 48 weeks following pioglitazone 
discontinuation (49).
Another important issue is whether all or some metabolic and histological benefits are 
sustainable with continued TZDs use. Following an initial 1 year rosiglitazone placebo 
controlled trial, 2 year extension of rosiglitazone therapy in subjects who received it for a 
year prior did not result in further improvement in histology despite continued improvement 
in insulin sensitivity and liver transaminases (42). Eagerly awaited are the final results from 
a study conducted by Dr. Ken Cusi’s group which administered pioglitazone 45 mg/day for 
18 months which presumably had a significant impact on steatosis, necroinflammation, and 
fibrosis.
Weight gain is the most common adverse event experienced by subjects with NASH during 
the TZD trials. Long term use of TZDs in patients with diabetes as raised safety concerns 
regarding the possible increase risk of congestive heart failure, bladder cancer, and bone 
fractures (50, 51). It has been suggested that pioglitazone may have a better cardiovascular 
profile than rosiglitazone presumably due to different effects on circulating lipids (52). 
Cautious use of pioglitazone is recommended by the current multi-society practice in non-
diabetic NASH patients (14).
C. Drugs with equivocal efficacy in NASH
Metformin
Metformin exhibits several effects that result in increased insulin sensitivity: it inhibits 
hepatic gluconeogenesis, enhances peripheral tissue utilization of glucose, reduces 
circulating free fatty acids, and decreases food intake and body weight (53–55).
Despite early reports of favorable effect on liver transaminases and histology, other studies 
failed to confirm metformin effects on liver histology (26, 56–58). The best and largest study 
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to examine the effect of metformin on NAFLD was the TONIC clinical trial (26). In this 
trial, 173 children (aged 8–17 years) with histologically proven NAFLD were randomized to 
receive metformin (1000 mg/day, n=57), vitamin E (800 IU/day, n=58), or placebo (n=58) 
for 96 weeks. The trial’s primary outcome, sustainable decrease in ALT, was not achieved in 
any group. In relation to liver histology, there was improvement in hepatocyte ballooning 
and NAS, and higher frequency of NASH resolution with both metformin and vitamin E, but 
these changes reached statistical significance only with vitamin E but not metformin therapy. 
Similarly, no effect for metformin on liver histology was noted in patients with NAFLD in a 
meta-analysis that pooled results from 4 studies (59).
Ursodeoxycholic acid (UDCA)
UDCA proposed mechanisms of action include altering bile acid pool, modulation of 
immune response, cell signaling and mitochondrial integrity in addition to potential anti-
inflammatory and anti-apoptotic effects (60).
Contrary to the early reports of favorable effects of low (12–15mg/kg/day) and high (28–35 
mg/kg/day) UDCA on liver biochemistries, steatosis and histology in NAFLD (22, 24, 61, 
62), larger studies failed to validate these findings. Two large randomized studies in patients 
with biopsy-confirmed NASH showed no significant effects for UDCA on NASH histology 
with low (13–15 mg/kg/day for 2 years, n=166) or high dose (23–28 mg/kg/day for 1.5 
years, n=185) UDCA (63, 64). Currently, there is no role for UDCA in patients with NASH.
Statins
Several small reports suggest that the HMG CoA reductase inhibitors, also known as statins, 
are safe when used in patients with NAFLD and have favorable effects on liver 
transaminases and hepatic steatosis on imaging (65–69). Improvement in NAFLD histology 
could not be consistently demonstrated in the small reported studies (70–72).
On the other hand, there is no evidence for increased hepatotoxicity when statins are used to 
treat dyslipidemia in patients with NAFLD or other chronic liver diseases (73–75). In a large 
study of dyslipidemic patients with elevated baseline liver transaminases who did (n=1342) 
or did not (n=2245) received statins, there was no difference in the incidence of 
hepatotoxicity over a 6 months follow up(74). The post-hoc analysis of the GREACE study 
evaluated 437 patients with increased liver biochemistry tests at baseline presumably due to 
NAFLD. The 227 who were treated with a statin (88% received atorvastatin) had substantial 
improvement in liver tests (p<0·0001) compared to the remaining 210 subjects whose liver 
tests did not improve. (73). The incidence of cardiovascular events was significantly lower 
compared to those with elevated liver tests who did not receive a statin (10% vs 30%, 
p<0.0001). The discontinuation of the statin due to rise in the transaminases to more than 
three-times the upper limit of normal per study protocol was reported in less than 1% of 
study subjects.
Fibrates
Fibrates activation of PPAR-α increases hepatic fatty acid oxidation and reduce hepatic 
triglyceride synthesis and VLDL production and export (76). The results of small studies 
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yielded inconsistent effects of fibrates on NAFLD on ALT (61, 77, 78). Despite decreasing 
plasma triglycerides and VLDL, there was no effect for fenofibrate on hepatic fat content in 
a short 8 weeks study (79). Data on fibrates effect on liver histology in NAFLD are also 
conflicting, with one study showing improvement only in ballooning while another study 
showed no effect on histology (61, 78).
Long-chain polyunsaturated fatty acids (LC-PUFA)
LC-PUFA in the n−3 (ω-3) series including docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA), are abundant in fish and fish oil supplements. LC-PUFA 
reduce triglycerides, adipose tissue inflammation, endothelial dysfunction, and increase 
HDL, adiponectin and insulin sensitivity (80–82). LC-PUFA desaturation is altered in rodent 
and human NASH with an increase in the pro-inflammatory (ω-6 pathway) and decrease in 
the anti-inflammatory (ω-3) pathways (83).
Several studies reported improvement of ALT and steatosis with LC-PUFA (84–89). The 
effect on hepatic steatosis but not ALT was corroborated in a meta-analysis of data pooled 
from these studies (90). In the WELCOME study 103 subjects with NAFLD were 
randomized to receive 15–18 months treatment with DHA+EPA (4 gm/day) (91). No 
significant decrease in hepatic fat content or serum markers of fibrosis was noted. 
Erythrocytes enrichment with DHA correlated with decreased hepatic fat content. No effects 
on ALT, liver histology or serum levels of Keratin-18, hyaluronic acid, C-reactive protein or 
insulin resistance were observed in a recent large multicenter trial that randomized 243 
subjects with biopsy proven NASH to placebo, EPA 1800 mg/day, or EPA 2700 mg/day for 
12 months (92). In another study from the United States which consisted of 41 non-cirrhotic 
NASH patients, n-3 fish oil administered for one year offered no histological benefit (93). 
Currently, there are no data supporting the use of fish oil to improve liver histology in 
patients with NASH.
Angiotensin antagonists
The renin-angiotensin system modulates hepatic stellate cells activation and fibrogenesis 
(94–96). There is emerging data to suggest that blocking this system may have an effect on 
NAFLD histology and particularly fibrosis. For example, the use of angiotensin-converting-
enzyme inhibitors (ACEI) or angiotensin-receptor blockers (ARB) for treatment of 
hypertension in patients with NAFLD was associated decreased hepatic fibrosis and 
ballooning in a recent small retrospective study (97). In another study, 150 patients with 
NAFLD were randomized to receive either losartan or amlodipine for 6 months followed by 
simvastatin (98). Significant reduction in ultrasound measured hepatic steatosis, visceral 
adipose tissue, and insulin resistance were observed with Losartan compared to amlodipine. 
Addition of simvastatin enhanced these effects. Treatment of 54 patients with NASH and 
hypertension for 20 months with valsartan or telmisartan improved ALT, HOMA and 
steatosis. Significant improvement in lobular inflammation, ballooning, NAS and fibrosis 
and was only seen with telmisartan (99). Although these results are encouraging, to date 
there have not been rigorously conducted randomized controlled trials of sufficiently length 
and histological end points to definitely define the role of ACEI and ARBs in NASH.
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Pentoxifylline
Based on its possible favorable effects on tumor necrosis factor-α, hepatic glutathione and 
hepatic inflammation (100–102), several studies have tested pentoxifylline as a potential 
therapy for NASH. Initial studies reported improvement in ALT as a treatment for NASH in 
a few small studies. Earlier reports suggested reduction of ALT and TNF-α (103, 104). Two 
small studies subsequently reported improvement in NASH histology with pentoxifylline 
(102, 105). However, these effects could not be demonstrated in another study in which there 
was no show significant improvement in NASH histology with pentoxifylline compared to 
placebo (106).
E. Emerging pharmacologic agents for NASH
Obeticholic acid (OCA)
OCA is a selective agonist of the bile acid nuclear receptor farnesoid X receptor (FXR). 
FXR biological effects include regulation of bile acids synthesis and transport, lipid and 
glucose homeostasis and hepatic inflammation (107, 108). In the first pilot human trial, 64 
patients with NAFLD and type 2 diabetes mellitus were randomized to receive placebo, 
OCA at 25 mg, or OCA at 50 mg orally once daily for 6 weeks (109). OCA therapy resulted 
in improved insulin sensitivity, ALT and serum markers of fibrosis in addition to resulting in 
weight loss. Subsequently, OCA was studied in a large randomized clinical trial (FLINT) 
that recruited 283 subjects with biopsy proven non-cirrhotic NASH (110). Subjects were 
randomized to receive OCA 25 mg orally daily or matching placebo for 72 weeks. Type 2 
diabetes was present in almost half of the study population. The primary outcome of this 
study was improvement in liver histology defined as a decrease in NAS by at least 2 points 
without worsening of fibrosis from baseline to the end of treatment. The trial’s design was 
modified midway after a planned interim analysis showed significant improvement in liver 
histology in subjects receiving OCA. As a result, it was deemed unnecessary to perform end 
of therapy liver biopsy on the last 64 subjects. Improvement in steatosis, lobular 
inflammation, ballooning and fibrosis was observed significantly more with OCA versus 
placebo (Figure 2). A significantly higher number of subjects achieved the primary study 
outcome on OCA as compared to placebo (45% versus 21%, relative risk 1.9, 95% CI 1.3 to 
2.8; p=0·0002). Resolution of NASH was observed more frequently with OCA than placebo 
(22 versus 13%), but this did not reach statistical significance (p=0.08) (Figure 2).
The most common adverse event with OCA therapy was pruritus, which was reported in 
23% on OCA versus 6% on placebo. In addition, a decrease in HDL and increase in total 
and LDL cholesterol were observed with OCA at 12 weeks of therapy. But these changes 
improved with therapy and resolved after stopping OCA. Patients receiving OCA also had a 
mild increase in alkaline phosphatase, similar to the prior pilot trial. Five severe or life 
threatening adverse events that were deemed related to OCA including possible cerebral 
ischemia (n=1), severe pruritus (n=3), and hyperglycemia (n=1). Two deaths in subjects 
receiving OCA were deemed not related to OCA; one from myocardial ischemia and another 
from sepsis and heart failure. OCA therapy was associated with a mean weight loss of 2.3 kg 
compared to no weight loss with placebo. Studies confirming the efficacy and demonstrating 
long term safety of OCA in NASH are being planned.
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Fibroblast growth factor 21
Fibroblast growth factor 21 (FGF21) is regulator of metabolism and energy homeostasis 
(111, 112). FGF21 administration improves hepatic steatosis, inflammation and fibrosis in 
murine models of NAFLD and NASH (113–115)., FGF21 administration resulted in 
improvements in hepatic necroinflammation and fibrosis, insulin sensitivity, and post-
prandial lipidemia n Ossabaw miniature swine with diet induced NASH (116). Authors are 
aware of two early phase clinical trials planned by Pharma in the United States in 2015–
2016. One difficulty with these agents is their parenteral route of administration.
Exenatide and liraglutide
Exenatide is a synthetic glucagon-like peptide-1 (GLP-1) agonist with regulatory effects on 
post-prandial insulin secretion and glucose metabolism (117). It reduces free fatty acid 
induced endoplasmic reticulum stress and apoptosis (118), and improves hepatic steatosis in 
patients with type 2 diabetes by improving sensitivity to fibroblast growth factor 21 (119–
121). An open label study of 8 patients with diabetes and biopsy proven NASH evaluated the 
effects of 28 weeks of exenatide on liver histology (122). There was improvement in NASH 
histological lesions and NAS redyction in 5 subjects. Fibrosis improved in 4 subjects (by 1 
stage in 3 subjects and by 2 stages in one subject). There is currently one registered trial 
(NCT02303730) that aims to test the effects of exenatide on hepatic fat content in Chinese 
patients with type 2 diabetes in comparison to insulin glargine.
Recent data offer encouraging results for liraglutide, another GLP-1 agonist. A small single 
arm, open-label Japanese study (LEAN-J) showed some histological benefit with 96 weeks 
of liraglutide treatment in 10 patients with NASH who had paired liver biopsies (X). At the 
most recent International Liver Congress (Vienna 2015), Dr. Phil Newsome’s group 
presented the final results of their LEAN trial which consisted of 52 patients with biopsy-
proven NASH and randomized participants to receive either 1.8 mg/day of liraglutide 
subcutaneously or placebo. The primary end of this trial, resolution of NASH with no 
worsening of fibrosis, was observed in 39% of patients receiving liraglutide as compared to 
9% in the placebo group (x). Full results of this study as a peer reviewed manuscript are 
awaited.
Cysteamine Bitartrate
Cysteamine is a glutathione precursor that is more effective at crossing cellular membranes 
than glutathione. It has a protective effect against acetaminophen-induced liver injury in 
humans (123, 124). Enteric coated cysteamine given for 24 weeks to 13 children with biopsy 
proven NAFLD and elevated ALT (125), resulted in normalization or significant > 50% 
reduction in ALT in 7 children associated with an increase in mean serum adiponectin level 
and a decrease in keratin-18 levels. There is currently an ongoing clinical trial of in children 
with biopsy proven NAFLD (NCT01529268) to evaluate the effects of 3 doses of cysteamine 
given for 52 weeks on NAFLD histology.
Simtuzumab
Lysyl oxidases (LOX) are a family of extracellular matrix crosslinking enzymes involved in 
crosslinking collagen and elastin. Simtuzumab is a humanized monoclonal antibody to LOX 
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like (LOXL) 2 (126). There are currently two clinical trials in patients with NASH and 
bridging fibrosis (NCT01672866) or cirrhosis (NCT01672879) evaluating simtuzumab’s 
safety and effects on hepatic venous pressure gradient, hepatic fibrosis, and overall and 
hepatic events free survival.
GR-MD-02
Galactin 3 protein is important in hepatic fibrogenesis. GR-MD-02 is a galactin 3 inhibitor 
that improved fibrosis and portal hypertension in toxin-induced cirrhosis, and resulted in 
regression of fibrosis in a murine model of NASH with fibrosis (127, 128). In a phase 1 trial 
in patients with NASH and bridging fibrosis,GR-MD-02 improved serum markers of fibrosis 
(FibroTest® and Keratin-18) and inflammatory markers (tumor necrosis factor-alpha and 
interleukin-6 and 8) in studied subjects (129). There no safety issues reported. A multicenter, 
phase 2 study of GR-MD-02 in patients with NASH cirrhosis is underway in the United 
States.
Cenicriviroc
Cenicriviroc (CVC) is an oral inhibitor of the C-C chemokine receptors (CCR) 2 and 5, 
which are involved in macrophage recruitment to the liver. It improves hepatic fibrosis and 
necroinflammation in a murine model of diet and streptozotocin induced NASHt (130). A 
phase 2 clinical trial (NCT02217475) that is currently evaluating the safety and efficacy of 
this agent in improving histology in patients with NASH and fibrosis but without cirrhosis.
Aramchol
Aramchol is a synthetic lipid molecule resulting from the conjugation of arachidic acid 
(saturated fatty acid) and cholic acid (bile acid). In rodent models of diet induced NAFLD, it 
suppresses stearoyl coenzyme Adesaturase 1 (SCD1) activity and improves hepatic 
steatosis(131, 132). In a recent controlled trial (133), 60 subjects with biopsy proven 
NAFLD were randomized to receive aramchol 100 mg or 300 mg daily versus placebo for 3 
months. Significant reduction in hepatic fat content as measured by magnetic resonance 
spectroscopy was noted in the 300 mg group compared to placebo. No significant 
improvement in ALT, insulin sensitivity or endothelial function was observed. There is 
currently an ongoing clinical trial (NCT02279524) in pre-diabetic or diabetic patients with 
biopsy proven NASH to investigate the effect of 52 weeks of Aramchol therapy (400 mg or 
600 mg once daily) on liver fat content and histology.
GFT505
GFT505 is a dual PPAR α and δ agonist that improves insulin sensitivity and exerts 
favorable effects on circulating lipids. Animal studies showed favorable effects for GFT505 
on NASH histology (134, 135). It improved hepatic steatosis, fibrosis, and inflammation in 
different models of NASH and hepatic fibrosis in rodents (136). GFT505 has also been 
shown to result in improvement in liver enzymes in subjects with the metabolic syndrome in 
phase II trial (136). A phase2 multicenter randomized clinical trial (GOLDEN-505, 
NCT01694849) was recently completed and its promising preliminary results became 
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available through the company’s press release (x) but full results are not yet available to the 
scientific community.
E. Conclusions
NAFLD importance as a clinical entity is continuing to increase and is resulting in increased 
utilization of liver transplantation. In addition to exercise and weight loss, vitamin E and 
pioglitazone have demonstrated efficacy in improving NASH histology in non-diabetic, non-
cirrhotic patients. This is an exciting time indeed in the field with multiple emerging 
promising pharmacologic therapies for NASH that are aimed not only at improving fibrosis 
but also underlying disturbed metabolic pathways. The results of these clinical trials are 
anxiously awaited to fill in the many unmet needs that exist in NASH therapy such as 
treatment of the patients with diabetes or those with cirrhosis.
Acknowledgments
Authors acknowledge that there may be inevitable similarities between this review article and other review articles/
text book chapters written by them on the same topic.
Drs. Chalasani and Gawrieh participate in multicenter clinical trials sponsored by various pharma in NASH. These 
clinical trials provide research grant support of their institution with no personal income.
References
1. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic 
steatohepatitis is the second leading etiology of liver disease among adults awaiting liver 
transplantation in the United States. Gastroenterology. 2015; 148(3):547–55. [PubMed: 25461851] 
2. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and 
outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. 
Gastroenterology. 2011; 141(4):1249–53. [PubMed: 21726509] 
3. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, et al. A systematic review of 
follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 
2013; 59(3):550–6. [PubMed: 23665288] 
4. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD 
progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for 
prognosis and clinical management. J Hepatol. 2015; 62(5):1148–55. [PubMed: 25477264] 
5. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty 
liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116(6):1413–
9. [PubMed: 10348825] 
6. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: 
a follow-up study. Hepatology. 1995; 22(6):1714–9. [PubMed: 7489979] 
7. Dam-Larsen S, Becker U, Franzmann MB, Larsen K, Christoffersen P, Bendtsen F. Final results of a 
long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol. 2009; 44(10):1236–43. 
[PubMed: 19670076] 
8. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the 
strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. 
Hepatology. 2015; 61(5):1547–54. [PubMed: 25125077] 
9. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term 
follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44(4):865–73. 
[PubMed: 17006923] 
10. Angulo P, Machado MV, Diehl AM. Fibrosis in nonalcoholic Fatty liver disease: mechanisms and 
clinical implications. Semin Liver Dis. 2015; 35(2):132–45. [PubMed: 25974899] 
Gawrieh and Chalasani Page 9
Semin Liver Dis. Author manuscript; available in PMC 2017 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
11. Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic 
criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related 
mortality. Hepatology (Baltimore, Md). 2011; 53(6):1874–82.
12. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. 
Liver Fibrosis, but no Other Histologic Features, Associates with Long-term Outcomes of Patients 
With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015
13. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and 
clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011; 54(1):344–53. [PubMed: 
21520200] 
14. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and 
management of non-alcoholic fatty liver disease: practice guideline by the American 
Gastroenterological Association, American Association for the Study of Liver Diseases, and 
American College of Gastroenterology. Gastroenterology. 2012; 142(7):1592–609. [PubMed: 
22656328] 
15. Chung MY, Yeung SF, Park HJ, Volek JS, Bruno RS. Dietary alpha- and gamma-tocopherol 
supplementation attenuates lipopolysaccharide-induced oxidative stress and inflammatory-related 
responses in an obese mouse model of nonalcoholic steatohepatitis. The Journal of nutritional 
biochemistry. 2010; 21(12):1200–6. [PubMed: 20138495] 
16. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-
beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot 
study. Aliment Pharmacol Ther. 2001; 15(10):1667–72. [PubMed: 11564008] 
17. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al. A pilot study of 
vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin 
Gastroenterol Hepatol. 2004; 2(12):1107–15. [PubMed: 15625656] 
18. Guy CD, Suzuki A, Abdelmalek MF, Burchette JL, Diehl AM. Treatment response in the PIVENS 
trial is associated with decreased Hedgehog pathway activity. Hepatology. 2015; 61(1):98–107. 
[PubMed: 24849310] 
19. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment 
improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003; 98(11):
2485–90. [PubMed: 14638353] 
20. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of 
the effects of lifestyle modification and vitamin E. Hepatology. 2003; 38(2):413–9. [PubMed: 
12883485] 
21. Yakaryilmaz F, Guliter S, Ozenirler S, Erdem O, Akyol G. Vitamin E treatment in patients with 
nonalcoholic steatohepatitis: A six-month, open-label study of sixteen patients. Current therapeutic 
research, clinical and experimental. 2004; 65(3):266–77.
22. Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, et al. Randomized placebo-
controlled trial of ursodeoxycholic Acid with vitamin e in nonalcoholic steatohepatitis. Clin 
Gastroenterol Hepatol. 2006; 4(12):1537–43. [PubMed: 17162245] 
23. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, 
Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. The New England journal of medicine. 
2010
24. Pietu F, Guillaud O, Walter T, Vallin M, Hervieu V, Scoazec JY, et al. Ursodeoxycholic acid with 
vitamin E in patients with nonalcoholic steatohepatitis: long-term results. Clinics and research in 
hepatology and gastroenterology. 2012; 36(2):146–55. [PubMed: 22154224] 
25. Wang CL, Liang L, Fu JF, Zou CC, Hong F, Xue JZ, et al. Effect of lifestyle intervention on non-
alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol. 2008; 14(10):1598–
602. [PubMed: 18330955] 
26. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of 
vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and 
adolescents: the TONIC randomized controlled trial. JAMA. 2011; 305(16):1659–68. [PubMed: 
21521847] 
27. Pacana T, Sanyal AJ. Vitamin E and nonalcoholic fatty liver disease. Current opinion in clinical 
nutrition and metabolic care. 2012; 15(6):641–8. [PubMed: 23075940] 
Gawrieh and Chalasani Page 10
Semin Liver Dis. Author manuscript; available in PMC 2017 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
28. Berry D, Wathen JK, Newell M. Bayesian model averaging in meta-analysis: vitamin E 
supplementation and mortality. Clinical trials. 2009; 6(1):28–41. [PubMed: 19254931] 
29. Dietrich M, Jacques PF, Pencina MJ, Lanier K, Keyes MJ, Kaur G, et al. Vitamin E supplement use 
and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart 
Study: Does the underlying health status play a role? Atherosclerosis. 2009; 205(2):549–53. 
[PubMed: 19195657] 
30. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: 
high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005; 
142(1):37–46. [PubMed: 15537682] 
31. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of 
antioxidant supplements for primary and secondary prevention: systematic review and meta-
analysis. JAMA. 2007; 297(8):842–57. [PubMed: 17327526] 
32. Gerss J, Kopcke W. The questionable association of vitamin E supplementation and mortality–
inconsistent results of different meta-analytic approaches. Cellular and molecular biology. 2009; 
55(Suppl):OL1111–20. [PubMed: 19267994] 
33. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and 
the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). 
JAMA. 2011; 306(14):1549–56. [PubMed: 21990298] 
34. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004; 351(11):1106–18. [PubMed: 15356308] 
35. Sharma AM, Staels B. Review: Peroxisome proliferator-activated receptor gamma and adipose 
tissue–understanding obesity-related changes in regulation of lipid and glucose metabolism. The 
Journal of clinical endocrinology and metabolism. 2007; 92(2):386–95. [PubMed: 17148564] 
36. Libby P, Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated 
receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol. 
2007; 99(4a):27b–40b.
37. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome 
proliferator-activated receptors. Endocrinology. 2003; 144(6):2201–7. [PubMed: 12746275] 
38. Orasanu G, Ziouzenkova O, Devchand PR, Nehra V, Hamdy O, Horton ES, et al. The peroxisome 
proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a 
peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. 
Journal of the American College of Cardiology. 2008; 52(10):869–81. [PubMed: 18755353] 
39. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic 
steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. 
Hepatology. 2003; 38(4):1008–17. [PubMed: 14512888] 
40. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. 
Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin 
clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004; 
53(8):2169–76. [PubMed: 15277403] 
41. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al. 
Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-
controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 
2008; 135(1):100–10. [PubMed: 18503774] 
42. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, et al. Long-term efficacy of 
rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone 
therapy (FLIRT 2) extension trial. Hepatology. 2010; 51(2):445–53. [PubMed: 19877169] 
43. Omer Z, Cetinkalp S, Akyildiz M, Yilmaz F, Batur Y, Yilmaz C, et al. Efficacy of insulin-
sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2010; 22(1):18–
23. [PubMed: 19667999] 
44. Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA. Rosiglitazone versus 
rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic 
steatohepatitis in humans: a 12-month randomized, prospective, open-label trial. Hepatology. 
2011; 54(5):1631–9. [PubMed: 21748770] 
Gawrieh and Chalasani Page 11
Semin Liver Dis. Author manuscript; available in PMC 2017 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
45. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of 
pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004; 39(1):188–96. 
[PubMed: 14752837] 
46. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial 
of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355(22):2297–
307. [PubMed: 17135584] 
47. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-
controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. 
Gastroenterology. 2008; 135(4):1176–84. [PubMed: 18718471] 
48. Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver 
histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 
2012; 35(1):66–75. [PubMed: 22050199] 
49. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, et al. The effects of 
discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology. 2007; 46(2):
424–9. [PubMed: 17559148] 
50. Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, et al. The use of pioglitazone and 
the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ (Clinical 
research ed). 2012; 344:e3645.
51. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative 
effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-
drug combinations. Ann Intern Med. 2011; 154(9):602–13. [PubMed: 21403054] 
52. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in 
patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. Jama. 2007; 298(10):
1180–8. [PubMed: 17848652] 
53. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean 
noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab. 1991; 73(6):1294–301. 
[PubMed: 1955512] 
54. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, et al. Metformin reduces weight, 
centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly 
obese subjects with body mass index greater than 30. Metabolism. 2001; 50(7):856–61. [PubMed: 
11436194] 
55. Pernicova I, Korbonits M. Metformin–mode of action and clinical implications for diabetes and 
cancer. Nature reviews Endocrinology. 2014; 10(3):143–56.
56. Haukeland JW, Konopski Z, Eggesbo HB, von Volkmann HL, Raschpichler G, Bjoro K, et al. 
Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand 
J Gastroenterol. 2009; 44(7):853–60. [PubMed: 19811343] 
57. Nair S, Diehl AM, Wiseman M, H FG Jr, Perrillo RP. Metformin in the treatment of non-alcoholic 
steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004; 20(1):23–8.
58. Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The Effect of Metformin and 
Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance 
and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. Therapeutic advances in 
gastroenterology. 2009; 2(3):157–63. [PubMed: 21180541] 
59. Rakoski MO, Singal AG, Rogers MA, Conjeevaram H. Meta-analysis: insulin sensitizers for the 
treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2010; 32(10):1211–21. 
[PubMed: 20955440] 
60. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‘mechanisms of action and clinical use 
in hepatobiliary disorders’. J Hepatol. 2001; 35(1):134–46. [PubMed: 11495032] 
61. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or 
clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 1996; 
23(6):1464–7. [PubMed: 8675165] 
62. Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, et al. A randomized 
controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 
2011; 54(5):1011–9. [PubMed: 21145828] 
Gawrieh and Chalasani Page 12
Semin Liver Dis. Author manuscript; available in PMC 2017 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
63. Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rossle M, Cordes HJ, et al. High-dose 
ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, 
placebo-controlled trial. Hepatology. 2010; 52(2):472–9. [PubMed: 20683947] 
64. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. 
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. 
Hepatology. 2004; 39(3):770–8. [PubMed: 14999696] 
65. Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, et al. 
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a 
randomised study. Current medical research and opinion. 2006; 22(5):873–83. [PubMed: 
16709309] 
66. Han KH, Rha SW, Kang HJ, Bae JW, Choi BJ, Choi SY, et al. Evaluation of short-term safety and 
efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum 
alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the 
effect on patients with hypercholesterolemia and mild to moderate hepatic damage). Journal of 
clinical lipidology. 2012; 6(4):340–51. [PubMed: 22836071] 
67. Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulos A, et al. 
Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with 
dyslipidemia. Indian journal of gastroenterology : official journal of the Indian Society of 
Gastroenterology. 2004; 23(4):131–4. [PubMed: 15333967] 
68. Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, et al. Ursodeoxycholic acid and 
atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol. 2003; 17(12):
713–8. [PubMed: 14679419] 
69. Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for 
the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical 
trial. Am J Gastroenterol. 2011; 106(1):71–7. [PubMed: 20842109] 
70. Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-
alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up 
study. Journal of hepatology. 2007; 47(1):135–41. [PubMed: 17400325] 
71. Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, et al. Efficacy of atorvastatin 
for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism. 2008; 57(12):
1711–8. [PubMed: 19013295] 
72. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the 
treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin 
Gastroenterol. 2009; 43(10):990–4. [PubMed: 19448566] 
73. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, et al. Safety and 
efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart 
disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation 
(GREACE) Study: a post-hoc analysis. Lancet. 2010; 376(9756):1916–22. [PubMed: 21109302] 
74. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes 
are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004; 126(5):1287–92. [PubMed: 
15131789] 
75. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-
dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: 
Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. 
Hepatology. 2007; 46(5):1453–63. [PubMed: 17668878] 
76. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of 
action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998; 98(19):2088–93. 
[PubMed: 9808609] 
77. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients 
with nonalcoholic steatohepatitis. J Hepatol. 1999; 31(2):384. [PubMed: 10453959] 
78. Fernandez-Miranda C, Perez-Carreras M, Colina F, Lopez-Alonso G, Vargas C, Solis-Herruzo JA. 
A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 
2008; 40(3):200–5. [PubMed: 18261709] 
Gawrieh and Chalasani Page 13
Semin Liver Dis. Author manuscript; available in PMC 2017 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
79. Fabbrini E, Mohammed BS, Korenblat KM, Magkos F, McCrea J, Patterson BW, et al. Effect of 
fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, 
and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 
2010; 95(6):2727–35. [PubMed: 20371660] 
80. Flachs P, Rossmeisl M, Bryhn M, Kopecky J. Cellular and molecular effects of n-3 polyunsaturated 
fatty acids on adipose tissue biology and metabolism. Clin Sci (Lond). 2009; 116(1):1–16. 
[PubMed: 19037880] 
81. Flachs P, Rossmeisl M, Kopecky J. The effect of n-3 fatty acids on glucose homeostasis and insulin 
sensitivity. Physiological research/Academia Scientiarum Bohemoslovaca. 2014; 63(Suppl 
1):S93–118.
82. Wu JH, Cahill LE, Mozaffarian D. Effect of fish oil on circulating adiponectin: a systematic review 
and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2013; 98(6):2451–9. 
[PubMed: 23703724] 
83. Lopez-Vicario C, Gonzalez-Periz A, Rius B, Moran-Salvador E, Garcia-Alonso V, Lozano JJ, et al. 
Molecular interplay between Delta5/Delta6 desaturases and long-chain fatty acids in the 
pathogenesis of non-alcoholic steatohepatitis. Gut. 2014; 63(2):344–55. [PubMed: 23492103] 
84. Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, et al. Prolonged n-3 
polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-
alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther. 2006; 23(8):1143–51. 
[PubMed: 16611275] 
85. Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, et al. Effects of n-3 
polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis. 2008; 
40(3):194–9. [PubMed: 18054848] 
86. Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified 
eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol. 2008; 
42(4):413–8. [PubMed: 18277895] 
87. Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from 
seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol. 
2008; 14(41):6395–400. [PubMed: 19009658] 
88. Sofi F, Giangrandi I, Cesari F, Corsani I, Abbate R, Gensini GF, et al. Effects of a 1-year dietary 
intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver 
disease patients: a preliminary study. International journal of food sciences and nutrition. 2010; 
61(8):792–802. [PubMed: 20465434] 
89. Nobili V, Alisi A, Della Corte C, Rise P, Galli C, Agostoni C, et al. Docosahexaenoic acid for the 
treatment of fatty liver: randomised controlled trial in children. Nutrition, metabolism, and 
cardiovascular diseases : NMCD. 2013; 23(11):1066–70.
90. Parker HM, Johnson NA, Burdon CA, Cohn JS, O’Connor HT, George J. Omega-3 
supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J 
Hepatol. 2012; 56(4):944–51. [PubMed: 22023985] 
91. Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, et al. Effects of purified 
eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: Results from the 
*WELCOME study. Hepatology. 2014
92. Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No significant effects of 
ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. 
Gastroenterology. 2014; 147(2):377–84.e1. [PubMed: 24818764] 
93. Argo CK, Patrie JT, Lackner C, Henry TD, de Lange EE, Weltman AL, et al. Effects of n-3 fish oil 
on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-
controlled trial. J Hepatol. 2015; 62(1):190–7. [PubMed: 25195547] 
94. Oakley F, Teoh V, Ching ASG, Bataller R, Colmenero J, Jonsson JR, et al. Angiotensin II activates 
I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver 
fibrosis. Gastroenterology. 2009; 136(7):2334–44.e1. [PubMed: 19303015] 
95. Moreno M, Gonzalo T, Kok RJ, Sancho-Bru P, van Beuge M, Swart J, et al. Reduction of advanced 
liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate 
cells in rats. Hepatology. 2010; 51(3):942–52. [PubMed: 20044807] 
Gawrieh and Chalasani Page 14
Semin Liver Dis. Author manuscript; available in PMC 2017 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
96. Macedo SM, Antunes Guimaraes T, Feltenberger JD, Santos SH. The role of renin-angiotensin 
system modulation on treatment and prevention of liver diseases. Peptides. 2014; 62c:189–96.
97. Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, et al. Renin-
angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int. 2014
98. Fogari R, Maffioli P, Mugellini A, Zoppi A, Lazzari P, Derosa G. Effects of losartan and 
amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic 
steatosis. Eur J Gastroenterol Hepatol. 2012; 24(2):164–71. [PubMed: 22081005] 
99. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as 
therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J 
Gastroenterol. 2009; 15(8):942–54. [PubMed: 19248193] 
100. Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM. Pentoxifylline attenuates 
steatohepatitis induced by the methionine choline deficient diet. J Hepatol. 2004; 41(4):592–8. 
[PubMed: 15464239] 
101. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP 3rd, Larrick J, et al. Cellular and 
molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem 
Biophys Res Commun. 1988; 155(3):1230–6. [PubMed: 2460096] 
102. Zein CO, Lopez R, Fu X, Kirwan JP, Yerian LM, McCullough AJ, et al. Pentoxifylline decreases 
oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic 
mechanism. Hepatology. 2012; 56(4):1291–9. [PubMed: 22505276] 
103. Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, et al. Beneficial effects of 
tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic 
parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2004; 99(10):1946–
52. [PubMed: 15447754] 
104. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic 
steatohepatitis. Am J Gastroenterol. 2004; 99(12):2365–8. [PubMed: 15571584] 
105. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves 
nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011; 54(5):
1610–9. [PubMed: 21748765] 
106. Van Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, et al. 
Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. 
Annals of hepatology. 2011; 10(3):277–86. [PubMed: 21677329] 
107. Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic 
steatohepatitis. Drug discovery today. 2012; 17(17–18):988–97. [PubMed: 22652341] 
108. Mazuy C, Helleboid A, Staels B, Lefebvre P. Nuclear bile acid signaling through the farnesoid X 
receptor. Cellular and molecular life sciences: CMLS. 2014
109. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, et al. Efficacy and safety 
of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and 
nonalcoholic fatty liver disease. Gastroenterology. 2013; 145(3):574–82.e1. [PubMed: 23727264] 
110. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. 
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic 
steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2014
111. Kharitonenkov A, Shanafelt AB. FGF21: a novel prospect for the treatment of metabolic diseases. 
Current opinion in investigational drugs. 2009; 10(4):359–64. [PubMed: 19337957] 
112. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 
as a novel metabolic regulator. J Clin Invest. 2005; 115(6):1627–35. [PubMed: 15902306] 
113. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, et al. Fibroblast growth factor 
21 corrects obesity in mice. Endocrinology. 2008; 149(12):6018–27. [PubMed: 18687777] 
114. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 
reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-
induced obese mice. Diabetes. 2009; 58(1):250–9. [PubMed: 18840786] 
115. Fisher FM, Chui PC, Nasser IA, Popov Y, Cunniff JC, Lundasen T, et al. Fibroblast Growth 
Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on 
Methionine and Choline-Deficient Diets. Gastroenterology. 2014
Gawrieh and Chalasani Page 15
Semin Liver Dis. Author manuscript; available in PMC 2017 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
116. Gawrieh S, Alloosh M, Sheridan R, Liang R, Masuoka H, Chalasani N, et al. Fibroblast growth 
factor 21 treatment improves atherogenic diet-induced liver injury and metabolic syndrome in 
Ossabaw miniature swine. Hepatology. 2014; 60:247A–9A.
117. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, et al. Synthetic exendin-4 
(exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 
diabetes. J Clin Endocrinol Metab. 2003; 88(7):3082–9. [PubMed: 12843147] 
118. Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA. GLP-1 analogs reduce hepatocyte steatosis 
and improve survival by enhancing the unfolded protein response and promoting 
macroautophagy. PloS one. 2011; 6(9):e25269. [PubMed: 21957486] 
119. Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M. Effects of 
combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity. 
2011; 19(12):2310–5. [PubMed: 21660077] 
120. Samson SL, Sathyanarayana P, Jogi M, Gonzalez EV, Gutierrez A, Krishnamurthy R, et al. 
Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver 
disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia. 2011; 
54(12):3093–100. [PubMed: 21956711] 
121. Li Y, Wong K, Giles A, Jiang J, Lee JW, Adams AC, et al. Hepatic SIRT1 attenuates hepatic 
steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. 
Gastroenterology. 2014; 146(2):539–49.e7. [PubMed: 24184811] 
122. Kenny PR, Brady DE, Torres DM, Ragozzino L, Chalasani N, Harrison SA. Exenatide in the 
treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J 
Gastroenterol. 2010; 105(12):2707–9. [PubMed: 21131943] 
123. Prescott LF, Newton RW, Swainson CP, Wright N, Forrest AR, Matthew H. Successful treatment 
of severe paracetamol overdosage with cysteamine. Lancet. 1974; 1(7858):588–92. [PubMed: 
4132259] 
124. Prescott LF, Sutherland GR, Park J, Smith IJ, Proudfoot AT. Cysteamine, methionine, and 
penicillamine in the treatment of paracetamol poisoning. Lancet. 1976; 2(7977):109–13. 
[PubMed: 59181] 
125. Dohil R, Schmeltzer S, Cabrera BL, Wang T, Durelle J, Duke KB, et al. Enteric-coated 
cysteamine for the treatment of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol 
Ther. 2011; 33(9):1036–44. [PubMed: 21395631] 
126. Van Bergen T, Marshall D, Van de Veire S, Vandewalle E, Moons L, Herman J, et al. The role of 
LOX and LOXL2 in scar formation after glaucoma surgery. Investigative ophthalmology & visual 
science. 2013; 54(8):5788–96. [PubMed: 23821193] 
127. Traber PG, Zomer E. Therapy of experimental NASH and fibrosis with galectin inhibitors. PloS 
one. 2013; 8(12):e83481. [PubMed: 24367597] 
128. Traber PG, Chou H, Zomer E, Hong F, Klyosov A, Fiel MI, et al. Regression of fibrosis and 
reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PloS 
one. 2013; 8(10):e75361. [PubMed: 24130706] 
129. Harrison S, Chalasani N, Lawitz E, Marri S, Noureddin M, Sanyal A, et al. Early phase 1 clinical 
trial results of GR-MD-02, a galec-tin-3 inhibitor, in patients having non-alcoholic steato-
hepatitis (NASH) with advanced fibrosis. Hepatology. 2014; 60:224A–7A. [PubMed: 24700550] 
130. Lefebvre E, Hashiguchi T, Jenkins H, Nabhan A, Yoneyama H, Friedman S, et al. Anti-fibrotic 
and anti-inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse 
model of NASH. Hepatology. 2013; 58(S1):219A–22A.
131. Gilat T, Leikin-Frenkel A, Goldiner I, Juhel C, Lafont H, Gobbi D, et al. Prevention of diet-
induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid 
conjugate (FABAC). Hepatology. 2003; 38(2):436–42. [PubMed: 12883488] 
132. Leikin-Frenkel A, Goldiner I, Leikin-Gobbi D, Rosenberg R, Bonen H, Litvak A, et al. Treatment 
of preestablished diet-induced fatty liver by oral fatty acid-bile acid conjugates in rodents. Eur J 
Gastroenterol Hepatol. 2008; 20(12):1205–13. [PubMed: 18989145] 
133. Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, et al. The fatty acid-bile 
acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver 
disease. Clin Gastroenterol Hepatol. 2014; 12(12):2085–91.e1. [PubMed: 24815326] 
Gawrieh and Chalasani Page 16
Semin Liver Dis. Author manuscript; available in PMC 2017 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
134. Cariou B, Staels B. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. 
Expert opinion on investigational drugs. 2014; 23(10):1441–8. [PubMed: 25164277] 
135. Quintero P, Arrese M. Nuclear control of inflammation and fibrosis in nonalcoholic 
steatohepatitis: therapeutic potential of dual peroxisome proliferator-activated receptor alpha/
delta agonism. Hepatology. 2013; 58(6):1881–4. [PubMed: 23787705] 
136. Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, et al. Hepatoprotective effects 
of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent 
models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013; 58(6):
1941–52. [PubMed: 23703580] 
Gawrieh and Chalasani Page 17
Semin Liver Dis. Author manuscript; available in PMC 2017 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure. 1. 
Effects of vitamin E and pioglitazone on liver histology in the PIVENS trial.
Footnote: * indicates statistical significance. LI: lobular inflammation, HB: hepatocellular 
ballooning. The primary outcome was improvement in histology defined as improvement by 
≥1 points in ballooning score, no increase in the fibrosis score, and either a decrease in the 
NAS to ≤3 points or a decrease in NAS of ≤2 points, with at least a 1 point decrease in either 
the lobular inflammation or steatosis score.
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Figure 2. 
Effects of obeticholic acid on liver histology in the FLINT trial.
Footnote: * indicates statistical significance. LI: lobular inflammation, HB: hepatocellular 
ballooning. The primary outcome was an improvement in histology defined as a decrease of 
≥2 points in NAS and no worsening in the fibrosis score;
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Table 1
Emerging therapeutic agents for NASH
Agent Putative mechanism/s Effects on NAFLD Studies in human 
NAFLD
Obeticholic acid FXR ligand Improves glucose and lipid 
metabolism
Improves histology including 
fibrosis
Yes
Fibroblast growth factor 21 Regulates glucose and lipid metabolism Improves histology in animal 
models including fibrosis
Not known
Exenatide and Liraglutide GLP-1 agonist Regulates glucose metabolism 
and post-prandial insulin sectretion
Improves histology including 
fibrosis
Yes. Recently 
presented liraglutide 
data offer exciting 
results.
Cysteamine Bitartrate glutathione precursor Antioxidant Improves ALT and keratin-18 Yes, Ongoing clinical 
trial
Simtuzumab LOXL2 antagonist Antifibrotic Unknown Yes, Ongoing clinical 
trial
GR-MD-02 galactin 3 inhibitor Improves fibrosis in murine 
models
Yes, Ongoing clinical 
trial
Cenicriviroc inhibitor of CCR 2 and 5 Improves hepatic inflammation 
and fibrosis on murine models
Yes, Ongoing clinical 
trial
Aramchol fatty acid–bile acid conjugate Inhibits stearoyl 
coenzyme A desaturase 1
Decreased hepatic fat content Yes, Ongoing clinical 
trial
GFT505 PPAR α and δ agonist Imporves insulin 
sensitivity and lipid metabolism
Improves hepatic steatosis, 
inflammation and fibrosis in 
murine models
Yes, the scientific 
results of the 
GOLDEN 505 trial are 
awaited
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